Table of Content



1 Relevant Concepts of Palbociclib
1.1 Indications for Palbociclib
1.2 Development of Palbociclib in China
1.3 Governmental Approval of Palbociclib in China
1.4 The Impact of COVID-19 on Palbociclib sales in China


2 Sales of Palbociclib in China, 2018-2020
2.1 Sales Value of Palbociclib
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Palbociclib
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Regions
2.3 Sales of Palbociclib by Dosage Form in China, 2018-2020
2.3.1 Capsule
2.3.2 Analysis of Other Dosage Forms


3 Analysis of Major Palbociclib Manufacturers in China, 2018-2020
3.1 Analysis of Market Share of Major Palbociclib Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Pfizer Europe MA EEIG
3.2.1 Enterprise Profile
3.2.2 Sales of IBRANCE (Pfizer’s Palbociclib) in China


4 Prices of Palbociclib for Different Manufacturers in China, 2020-2021
4.1 Pfizer Europe MA EEIG (IBRANCE)


5 Prospect of Chinese Palbociclib drug Market, 2021-2025
5.1 Influential Factors of Chinese Palbociclib Market Development
5.1.1 The Impact of COVID-19 on Chinese Palbociclib Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

List of Charts
Chart Patent Information About Palbociclib Capsule Registration in China
Chart Sales Value of Palbociclib Capsule over the World
Chart Sales Value of Palbociclib Capsule in China, 2018-2020
Chart Sales Value of Palbociclib Capsule in China by Regions, 2018-2020
Chart Sales Volume of Palbociclib Capsule in China, 2018-2020
Chart Sales Volume of Palbociclib Capsule in China by Regions, 2018-2020
Chart Market Share by Sales Value of Top Palbociclib Manufacturers in China, 2018-2020
Chart Sales Value and Volume of IBRANCE in China, 2018-2020
Chart Referential Prices of IBRANCE in China, 2020-2021
Chart Forecast on Sales Value of Palbociclib in China, 2021-2025
Chart Forecast on Sales Volume of Palbociclib in China, 2021-2025